Exploring Female Relatives of Patients with Hemophilia' Awareness, Attitudes, and Understanding Towards Genetic Testing
Hua Zhao,Wen-Jing Geng,Rui-Hong Wu,Zhen-Zhen Li
DOI: https://doi.org/10.2147/jmdh.s430984
2024-02-17
Journal of Multidisciplinary Healthcare
Abstract:Hua Zhao, 1 Wen-Jing Geng, 2 Rui-Hong Wu, 3 Zhen-Zhen Li 3 1 College of Nursing, Shanxi University of Chinese Medicine, Jinzhong, Shanxi, People's Republic of China; 2 Nursing Department, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi, People's Republic of China; 3 Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China Correspondence: Hua Zhao, College of Nursing, Shanxi University of Chinese Medicine, Jinzhong, Shanxi, 030619, People's Republic of China, Tel +86 13903465019, Email Purpose: A better understanding of the factors that influence engagement is needed to provide a reference for conducting genetic testing in female relatives of patients with hemophilia (PWH). We therefore determined the perceptions and understanding of genetic testing among female relatives of PWH in China. Methods: We carried out a qualitative study using in-depth, semi-structured interviews with 11 female relatives of PWH in Shanxi Province, China. The resulting data were analyzed using thematic analyses. Results: This study extracted four topics: uncertainty about carrier genetic status; limited understanding of genetic testing; coexistence of positive and negative coping; and multi-aspect demands. Conclusion: Healthcare professionals should provide personalized and multidimensional health education and comprehensive decision-making support to female relatives of PWH, to enhance their motivation and willingness to undergo genetic testing. It is also important to actively improve relevant policies, strengthen the genetic testing service system, and promote the popularization of genetic testing in female relatives of PWH. Keywords: hemophilia, female, genetic testing, attitudes, qualitative study Hemophilia is an X-linked recessive genetic bleeding disorder caused by a deficiency or decrease in the activity of coagulation factor VIII or IX. Hemophilia can be divided into hemophilia A (HA) and hemophilia B (HB), and can be severe (factor level <1 IU/dL), moderate (1–5 IU/dL), or mild (5–40 IU/dL), depending on the clotting factor concentration. 1 An annual global survey 2022 by The World Federation of Hemophilia (WFH) reported 257,146 patients with hemophilia (PWH) in 125 countries. HA and HB comprise 81.26% (208,957/257,146) to 16.41% (42,203/257,146) of PWH, with the remaining 2.33% (5,986/257,146) attributed to hemophilia of type unknown or type not reported. 2 The reported prevalence of hemophilia was 2.73–3.09 per 100,000 population in China, with approximately 120,000 PWH, with approximately 40,000 cases currently registered. 3,4 Shanxi Province in northern China covers an area of 156,700 km 2 , with a population of 34.91 million, and is considered to be an underdeveloped province. The Shanxi Hemophilia Treatment Center (HTC) was established in 2009, and a multidisciplinary team was subsequently developed. The HTC is responsible for managing the medical records of PWH, including the collection and reporting of information related to diagnosis, treatment, nursing care, education, and access to coagulation factors. A total of 902 PWH have been registered thus far. The main clinical characteristic of hemophilia is bleeding (spontaneous or after trauma) into major joints such as the ankles, knees and elbows, while some patients with severe hemophilia may also have intracranial or internal organ bleeds. 5 The treatment of hemophilia is based on replacement therapy with coagulation factor products. However, PWH in developing countries face many challenges and barriers to obtaining adequate treatment, and may thus suffer from different degrees of chronic damage to the musculoskeletal system, resulting in severe handicaps and even death. 6,7 Other complications, such as the development of inhibitory antibodies, further increase the complexity and costs of managing the disease. 8 Available data from medium- and high-income countries show life-expectancy disadvantages of people with HA and HB of 30% and 24%, respectively, compared with the rest of the population, with a much greater disadvantage in countries with more limited access to treatments for hemophilia. 9 These findings suggest that, in addition to its clinical burden, hemophilia also places a significant economic burden on healthcare payers, patients/caregivers, and society. 10 Hemophilia is usually inherited, with up to 30% of babies with hemophilia having no family history of the disorder, while the remaining 70% are born into families where hemophilia has been diag -Abstract Truncated-
health care sciences & services